File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis

TitleBetter survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis
Authors
KeywordsHepatocellular carcinoma
Unresectable
Stereotactic body radiation therapy
Transarterial chemoembolization
Outcomes
Issue Date2019
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/suronc
Citation
Surgical Oncology, 2019, v. 28, p. 228-235 How to Cite?
AbstractBackground This study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation therapy (SBRT) after TACE (TACE + SBRT). Methods This was a retrospective study of 2 centers in Hong Kong. There were 49 patients who had TACE + SBRT and 202 patients who had TACE alone. Propensity score matching was used to adjust for differences in patients’ demographics and tumor characteristics between the 2 groups. The primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS) and treatment-related toxicity. Results After matching, 49 patients were in the TACE + SBRT group and 98 patients in the TACE group with similar baseline characteristics. The 1-&3-year OS were better in TACE + SBRT group (67.2 vs. 43.9% and 36.5 vs. 13.3%, p = 0.003). The 1-&3-year PFS was also better in TACE + SBRT group (32.5 vs. 21.4% and 15.1 vs. 5.1%, p = 0.012). Radiological disease control was better in the TACE + SBRT group (98 vs. 56.7%). Risk of severe toxicity was uncommon in both treatment arms. TACE + SBRT was an independent good prognostic factor for OS and PFS in multivariate analysis, whereas AFP>200 ng/ml, large tumor and multiple tumors predicted worse OS. Conclusion TACE + SBRT is safe and results in better survivals in nonresectable HCC patients.
Persistent Identifierhttp://hdl.handle.net/10722/271414
ISSN
2017 Impact Factor: 2.558
2015 SCImago Journal Rankings: 1.475

 

DC FieldValueLanguage
dc.contributor.authorWong, TCL-
dc.contributor.authorChiang, CL-
dc.contributor.authorLee, AS-
dc.contributor.authorLee, VHF-
dc.contributor.authorYeung, CSY-
dc.contributor.authorHo, CHM-
dc.contributor.authorCheung, TT-
dc.contributor.authorNg, KKC-
dc.contributor.authorChok, SH-
dc.contributor.authorChan, ACY-
dc.contributor.authorDai, WC-
dc.contributor.authorWong, FCS-
dc.contributor.authorLuk, MY-
dc.contributor.authorLeung, TW-
dc.contributor.authorLo, CM-
dc.date.accessioned2019-06-24T01:09:25Z-
dc.date.available2019-06-24T01:09:25Z-
dc.date.issued2019-
dc.identifier.citationSurgical Oncology, 2019, v. 28, p. 228-235-
dc.identifier.issn0960-7404-
dc.identifier.urihttp://hdl.handle.net/10722/271414-
dc.description.abstractBackground This study compared outcomes of nonresectable hepatocellular carcinoma (HCC) who had transarterial chemoembolization (TACE) vs. stereotactic body radiation therapy (SBRT) after TACE (TACE + SBRT). Methods This was a retrospective study of 2 centers in Hong Kong. There were 49 patients who had TACE + SBRT and 202 patients who had TACE alone. Propensity score matching was used to adjust for differences in patients’ demographics and tumor characteristics between the 2 groups. The primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS) and treatment-related toxicity. Results After matching, 49 patients were in the TACE + SBRT group and 98 patients in the TACE group with similar baseline characteristics. The 1-&3-year OS were better in TACE + SBRT group (67.2 vs. 43.9% and 36.5 vs. 13.3%, p = 0.003). The 1-&3-year PFS was also better in TACE + SBRT group (32.5 vs. 21.4% and 15.1 vs. 5.1%, p = 0.012). Radiological disease control was better in the TACE + SBRT group (98 vs. 56.7%). Risk of severe toxicity was uncommon in both treatment arms. TACE + SBRT was an independent good prognostic factor for OS and PFS in multivariate analysis, whereas AFP>200 ng/ml, large tumor and multiple tumors predicted worse OS. Conclusion TACE + SBRT is safe and results in better survivals in nonresectable HCC patients.-
dc.languageeng-
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/suronc-
dc.relation.ispartofSurgical Oncology-
dc.subjectHepatocellular carcinoma-
dc.subjectUnresectable-
dc.subjectStereotactic body radiation therapy-
dc.subjectTransarterial chemoembolization-
dc.subjectOutcomes-
dc.titleBetter survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis-
dc.typeArticle-
dc.identifier.emailWong, TCL: wongtcl@hku.hk-
dc.identifier.emailChiang, CL: chiangcl@hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailNg, KKC: kkcng@hku.hk-
dc.identifier.emailChok, SH: chok6275@hku.hk-
dc.identifier.emailChan, ACY: acchan@hku.hk-
dc.identifier.emailDai, WC: daiwc@hku.hk-
dc.identifier.emailLuk, MY: myluk@hkucc.hku.hk-
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.authorityWong, TCL=rp01679-
dc.identifier.authorityChiang, CL=rp02241-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.authorityCheung, TT=rp02129-
dc.identifier.authorityNg, KKC=rp02390-
dc.identifier.authorityChok, SH=rp02110-
dc.identifier.authorityChan, ACY=rp00310-
dc.identifier.authorityLo, CM=rp00412-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.suronc.2019.01.006-
dc.identifier.pmid30851906-
dc.identifier.scopuseid_2-s2.0-85062148243-
dc.identifier.hkuros297967-
dc.identifier.volume28-
dc.identifier.spage228-
dc.identifier.epage235-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats